Transdermal delivery of the active enantiomer of ketorolac

• US 5,589,498 A
• Filed: 06/06/1995
• Issued: 12/31/1996
• Est. Priority Date: 11/09/1992
• Status: Expired due to Fees

• Current Assignee: Neurogesx, Inc.
• Original Assignee: Pharmetrix Corporation
• Inventors: Baker, Richard W., Mohr, Judy M., Nakaji, Lisa A.
• Primary Examiner(s): Cintins, Marianne M.
• Assistant Examiner(s): Jarvis, William R. A.
• Application Number:
  US08/470,648
• Time in Patent Office: 574 Days
• Field of Search: 514/413, 424/449
• US Class Current: 514/413
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/275 Nitriles; Isonitriles
• CPC Class Codes: A61K 31/37 Coumarins, e.g. psoralen
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 9/7061 Polyacrylates
• CPC Class Codes: A61K 9/7069 obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

The invention provides for the transdermal delivery of the active enantiomer of the analgesic ketorolac. Transdermal patches according to the invention are capable of delivering (-) ketorolac to a patient at therapeutically effective levels, at a flux rate of 20 μg/cm².hr or more. Patches for use in the present invention may be adhesive matrix, monolithic matrix, or liquid reservoir transdermal patches.

Claims

1. A patch for the transdermal administration of ketorolac and through a patient'"'"'s skin for a period of 12 hours or more, said patch comprising:

(a) an occlusive backing layer having a skin-facing side, and

(b) a drug depot having a skin-facing side and a skin-distal side in contact with said skin-facing side of said backing layer, said depot comprising,

i. (-) ketorolac,

ii. an enhancer combination comprising a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of propylene glycol, glycerin and butanol, and

iii. an adhesive polymer in which said (-) ketorolac and said enhancer are dispersed,

wherein said patch delivers (-) ketorolac through the skin facing side of said patch and through said patient'"'"'s skin at a flux rate of about 20 g/cm².hr or more.

2. The patch of claim 1 having an active surface area of less than 30 cm².

3. The patch of claim 1 wherein said plasticizing-type enhancer is isopropyl myristate.

4. The patch of claim 1 wherein said solvent-type enhancer is propylene glycol.

5. A patch for the transdermal administration of ketorolac through a patient'"'"'s skin for a period of 12 hours or more, said patch comprising:

(a) an occlusive backing layer having a skin-facing side, and

(b) a drug depot having a skin-facing side and a skin-distal side in contact with said skin-facing side of said backing layer, said depot comprising;

i. (-) ketorolac,

ii. an enhancer combination comprising a first portion of a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol, and

iii. polymer in which said (-) ketorolac and said enhancer are dispersed,

(c) an adhesive layer comprising an adhesive and a second portion of said plasticizing-type enhancer, said adhesive layer in contact with said skin-facing side of said depot,

wherein said patch delivers (-) ketorolac through the skin facing side of said patch and through said patient'"'"'s skin at a flux rate of about 20 μ

g/cm².hr or more.

6. The patch of claim 5 having an active surface area of less than 30 cm².

7. The patch of claim 5 wherein said plasticizing-type enhancer is isopropyl myristate.

8. The patch of claim 5 wherein said solvent enhancer is ethanol.

9. The patch of claim 5 wherein said polymer is a hydrogel.

10. The patch of claim 5 further comprising:

(d) a porous membrane having a skin-facing side and a skin-distal side in contact with said skin-facing side of said depot said membrane being permeable to said (-) ketorolac and said enhancer.

11. The patch of claim 10 wherein said porous membrane is a non-woven polyester.

12. A patch for the transdermal administration of ketorolac through a patient'"'"'s skin for a period of 12 hours or more, said patch comprising:

(a) an occlusive backing layer having a skin-facing side and a peripheral edge,

(b) a drug depot having a skin-facing side and a skin-distal side in contact with said skin-facing side of said backing layer, said depot comprising;

i. (-) ketorolac, and

ii. an enhancer combination in which said (-) ketorolac is dispersed, said enhancer combination comprising a first portion of a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol,

(c) a porous membrane permeable to said ketorolac and said enhancer, said membrane having a skin-facing side, a skin-distal side, and a peripheral edge, said skin-distal side of said membrane being in contact with said skin-facing side of said depot, and said peripheral edge of said membrane being sealed to said peripheral edge of said backing layer, and

(d) an adhesive layer comprising an adhesive and a second portion of said plasticizing-type enhancer, said adhesive layer being in contact with said skin-facing side of said porous membrane,

wherein said patch delivers (-) ketorolac through the skin facing side of said patch and through said patient'"'"'s skin at a flux rate of about 20 μ

g/cm².hr or more.

13. The patch of claim 12 wherein said plasticizing-type enhancer is isopropyl myristate.

14. The patch of claim 12 wherein said solvent-type enhancer is ethanol.

15. The patch of claim 12 wherein said depot further comprises:

iii. a foam material,

said (-) ketorolac and said enhancer being contained in said foam material.

16. The patch of claim 12 wherein said porous membrane is a non-woven polyester.

17. A method of administering ketorolac to a patient in need of such administration, comprising:

(a) applying to the skin of said patient a transdermal patch having a skin-facing side, said patch comprising;

i. an occlusive backing layer having a skin-facing side, and

ii. a drug depot having a skin-distal side in contact with said skin-facing side of said backing layer, said drug depot containing (-) ketorolac and an enhancer combination comprising a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol, and

(b) delivering (-) ketorolac through the skin facing side of said patch and through said patient'"'"'s skin at a flux rate of about 20 μ

g/cm².hr or more.

18. The method of claim 17 wherein said patch has an active surface area of less than 30 cm².

19. The method of claim 17 wherein less than 30 mg of (-) ketorolac is delivered to said patient over a 24 hour period.